QIAGEN have announced the European launch of their next-generation platform for syndromic insights, QIAstat-Dx®, with data being presented at ECCMID demonstrating early success.
A new study has evaluated a point-of-care diagnostic for syphilis and yaws in the Solomon Islands, where previously only serological tests requiring specialist equipment have been available.
Discover our highlights and key takeaways from the Microbiology Society Annual Conference with our Editor, Martha Powell, who runs through some of our favorite talks.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
A novel initiative is working to ensure that approximately 1 billion individuals are vaccinated against yellow fever across 27 African countries by 2026.
New research has suggested that a protein involved in Alzheimer’s disease may also be implicated in HIV-associated neurological disorders, suggesting Alzheimer’s therapies may benefit a subset of HIV patients.
New research has identified growth-restoring mutations in ceftriaxone-resistant gonorrhoea strains, providing insight into this bacteria’s evolution and raising concerns over the spread of this ‘superbug’.
With Zika research primarily focusing on in utero infections, new work has used a monkey model to study infants infected in their first year of life, uncovering adverse neurological consequences.
A new study has identified seven core elements they believe to be fundamental to effective antimicrobial stewardship programs across both high- and low-income settings.
Mylan N.V have announced they’ll be launching their third HIV combination in the US, following FDA approval of their once-daily treatment Symfi™.